Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17): A non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography

Anti-Cancer Drug Design

Volumn 13, Issue 6, 1998, Pages 703-730

  Aboagye, Eric O ^a   Kelson, Andrew B ^b   Tracy, Michael ^b   Workman, Paul ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SRI INTERNATIONAL   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

2 nitroimidazole; Drug design; Hypoxia; MRI; MRS; SR 4554

Indexed keywords

2 (2 NITRO 1 IMIDAZOLYL) N (3,3,3 TRIFLUORO 2 HYDROXYPROPYL)ACETAMIDE; FLUORINE; RADIOSENSITIZING AGENT;

ARTHRITIS; BRAIN TUMOR; CANCER; CANCER CHEMOTHERAPY; DIAGNOSTIC VALUE; GENE THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROGEN BOND; HYPOXIA; ISCHEMIC HEART DISEASE; LIVER MICROSOME; MEASUREMENT; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION POTENTIAL; OXYGEN SUPPLY; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; STROKE; TREATMENT OUTCOME; TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANIMALS; CELL HYPOXIA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR PROBES; NEOPLASMS; NITROIMIDAZOLES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031709082     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. ABOAGYE, E.O., LEWIS, A.D, JOHNSON, A, WORKMAN, P., TRACY, M. & HUXHAM, I.M (1995a). The novel fluorinated 2-nitroimidazole hypoxia probe SR 4554: reductive metabolism and semi-quantitative localization in human ovarian cancer multicellular spheroids as measured by electron energy loss spectroscopic analysis. British Journal of Cancer, 72, 312.
2. ABOAGYE, E.O., GRAHAM, M A., LEWIS, A D., TRACY, M., KELSON, A.B. & WORKMAN, P. (1995b). Development and validation of a solid phase extraction and high performance liquid Chromatographic assay for a novel fluorinated 2-nitroimidazole hypoxia probe SR 4554 in BALB/c mouse plasma. Journal of Chromatography: Biomedical Applications, 672, 125.
3. ABOAGYE, E.O., LEWIS, A.D., GRAHAM, M,A., TRACY, M, KELSON, A B., RYAN, K.J. & WORKMAN, P. (1996). Pharmacokinetics, bioavailability and biodistribution in mice of the novel fluorinated 2-nitroimidazole SR 4554. Anti-Cancer Drug Design, 11, 231.
4. ABOAGYE, E.O., LEWIS, A.D., TRACY, M. & WORKMAN, P. (1997a). Bioreductive metabolism of the novel fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554). Biochemical Pharmacology, 54, 1217.
5. ABOAGYE, E O., MAXWELL, R.J, KELSON, A.B., TRACY, M., LEWIS, A.D., GRAHAM, M A., HORSMAN, M.R., GRIFFITHS, JR. & WORKMAN, p. (1997b). Pre-clinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR 4554) as a probe for the measurement of tumor hypoxia. Cancer Research, 57, 3314.
6. ABOAGYE, E.O., MAXWELL, R.J., HORSMAN, M.R , LEWIS, A D, WORKMAN, P, TRACY, M. & GRIFFITHS, J.R. (1998). The relationship between tumor oxygenation determined by oxygen electrode measurements and magnetic resonance spectroscopy of the fluorinated 2-nitroimidazole SR 4554. British Journal of Cancer, 77, 65.
7. ADAMS, G.E., CLARKE, E.D., GRAY, P, JACOBS, R.S., STRATFORD, IJ., WARDMAN, P. & WATTS, M.E. (1979). Structure-activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio. International Journal of Radiation Biology, 35, 151.
8. BAISH, J.W., GAZIT, Y., BERK, DA., NOZUE, M., BAXTER, L.T. & JAIN, R.K. (1996). Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvascular Research, 51, 327.
9. BHUJWALLER, Z.M., TOZER, G.M., FIELD, S.B., MAXWELL, R.J. & GRIFFITHS, J.R. (1990). The energy metabolism of RIF-1 tumors following hydralazine. Radiotherapy and Oncology, 19, 281.
10. BIAGLOW, J., VARNES, M., ROIZEN-TOWLE, L., CLARKE, E., EPP, E., ASTOR, M. & HALL, E. (1986). Biochemistry of reduction of nitroheterocycles. Biochemical Pharmacology, 35, 77.
11. BRIZEL, D.M., ROSNER, G.L., PROSNITZ, L.R. & DEWHIRST, M.W (1995). Patterns and variability of tumor oxygenation in human soft tissue sarcomas, cervical carcinomas and lymph node metastases. International Journal of Radiation Oncology Biology Physics, 32, 1121.
12. BRIZEL, D.M , SCULLY. SP., HARRELSON, J.M., LAYFIELD, L.J., BEAN, JM., PROSNITZ, L.R. & DEWHIRST, M.W. (1996) Tumor oxygenation predicts for the likelihood of distance metastases in human soft tissue sarcoma. Cancer Research, 56, 941.
13. BROWN, J.M & WORKMAN, p. (1980). Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiation Research, 82, 171.
14. CHAPMAN, JD. (1991). Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiotherapy and Oncology, 20, S13.
15. CHAPMAN, J.D., FRANKO, A.J. & SHARPLIN, J. (1981). A marker for hypoxic cells in tumors with potential clinical applicability. British Journal of Cancer, 43, 546.
16. CHAPMAN, J.D., BAER, K. & LEE, J (1983). Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells Cancer Research, 43, 1523.
17. COLEMAN, C.N , WASSERMAN, T.H., URTASUN, R.C, HALSEY, J., HIRST, V.K , HANCOCK, S. & PHILIPS, T.L. (1986). Phase I trial of the hypoxic cell radiosensitizer SR 2508: the results of the five to six weeks schedule. International Journal of Radiation Oncology Biology Physics, 12, 1105.
18. DABROW, M.B., KATZ, H., O'DWYER, P.J., AFSHAR, C. & GLUSKER, J.P (1993). Molecular dimensions and properties of N-[1-(2-hydroxyethyl)-2-nitro-1-H-imidazol-1-yl]acetamide (SR 2508). Archives of Biochemistry and Biophysics, 302, 259.
19. 19F inversion-recovery echo planar imaging of perfluoro-15-crown-5-ether. Magnetic Resonance in Medicine, 32, 88.
20. DAVIDSON, A.G. (1988). Chromatography. In Practical Pharmaceutical Chemistry. Beckett, A.H. & Stenlake, J.B. (eds), vol. 2, p. 120. Athlone Press: London.
21. EVANS, S.M., JOINER, B, JENKINS, WT., LAUGHLIN, K.M., LORD, E.M. & KOCH, C.J. (1995). Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H -imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. British Journal of Cancer, 72, 875.
22. EVANS, S.M., JENKINS, W.T., JOINER, B , LORD, E M. & KOCH, C J. (1996). 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Research, 56, 405.
23. EVANS, S.M., JENKINS, W.T. SHAPIRO, M. & KOCH, C.J. (1997). Evaluation of the concept of 'hypoxic fraction' as a descriptor of tumor oxygenation status. Advances in Experimental Medicine and Biology, 411, 215.
24. FISHMAN, JE., JOSEPH, P.M., CARVLIN M.J., SAADI-ELMANDJRA, M , MUKHERJI, B & SLOVITER, H A. (1989). In vivo measurements of vascular oxygen tension in tumors using a fluorinated blood substitute. Investigative Radiology, 24, 65.
25. FRANKO, A.J. (1986). Misonidazole and other hypoxia markers: metabolism and applications International Journal of Radiation Oncology Biology Physics, 12, 1195.
26. FRANKO, A.J. & KOCH, C.J. (1984). Binding of misonidazole to V79 spheroids and fragments of Dunning rat prostatic and human colon carcinomas in vitro: diffusion of oxygen and reactive metabolites. International Journal of Radiation Oncology Biology Physics, 10, 1333.
27. FRANKO, A.J., KOCH, C.J., GARRECHT, B M , SHARPLIN, J. & HUGHES, D (1987). Oxygen dependence of binding of misonidazole to rodent and human tumors in vitro. Cancer Research, 47, 5367.
28. FRANKO, A J, KOCH, C.J. & BOISVERT, D P.J. (1992). Distribution of misonidazole adducts in 9L gliosarcoma tumors and spheroids: implications for oxygen distribution. Cancer Research, 52, 3831.
29. 31P NMR spectroscopy measurements, tumor size, hypoxic fraction and cell survival after radiotherapy. International Journal of Radiation Oncology Biology Physics, 18, 1341.
30. 14C-misonidazole. British Journal of Radiology, 56, 745.
31. GRAEBER, T.G, OSMANIAN, C , JACKS T., HOUSMAN, D.E., KOCH, C.K., LOWE, S W. & GIACCIA, A.J. (1996). Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumors. Nature, 379, 88.
32. GREENSTOCK, C.L., BIAGLOW, J.E. & DURAND, R.E (1978). Effects of sensitizers on cell respiration: II. The effects of hypoxic cell sensitizers on oxygen utilization in cellular and chemical models. British Journal of Cancer, 37, 11.
33. HALL, E.J. (1988). The oxygen effect and reoxygenation. In Radiobiology for Radiologist. Hall, E.J. (ed.), p. 137. Lippencott: Philadelphia.
34. 19F NMR relaxometry of a perfluorocarbon emulsion. Magnetic Resonance in Medicine, 29, 303.
35. 2 predicts survival in advanced cancer of the uterine cervix. Radiotherapy and Oncology, 26, 45.
36. HŌCKEL, M., SCHLENGER, K., ARAL, B., MITZE, M., SCHÄFFER, U. & VAUPEL, P. (1996). Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Research, 56, 4509.
37. HODGKISS, R.J. (1998). Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anti-Cancer Drug Design, 13, 687.
38. HONESS, D.J. & BLEEHEN, N M. (1991). Effects of two blood flow modifiers, hydralazine and flavone acetic acid, on KHT tumors and normal tissues in mice. International Journal of Radiation Biology, 60, 249.
39. HORSMAN, M.R., NORDSMARK, M., KHALIL, A A., HILL, S.A., CHAPLIN, D J, SIEMANN, D W & OVERGAARD, J. (1994). Reducing acute and chronic hypoxia in tumors by combining nicotinamide with carbogen breathing. Acta Oncologica, 33, 371.
40. HORSMAN, M.R., KHALIL, A.A . NORDSMARK, M., SIEMANN, D W., HILL, S., LYNCH, E.M., CHAPLIN, D.J., STERN, S , THOMAS, C.D., GUICHARD, M., GRAU, C. & OVERGAARD, J (1995a). The use of oxygen electrodes to predict radiobiological hypoxia in tumors. in Tumor Oxygenation. Vaupel, P.W., Kelleher, D.K. & Gunderoth, M. (eds), p. 50. Gustav Fischer Verlag: Stuttgart.
41. HORSMAN, M.R., GRAU C. & OVERGAARD, J. (1995b). Reoxygenation in a C3H mouse mammary carcinoma. The importance of chronic rather than acute hypoxia. Acta Oncologica, 34, 325.
42. JAIN, R.K. (1994). Barriers to drug delivery in solid tumors. Scientific American, 271, 58,
43. 19F magnetic resonance spectroscopy. International Journal of Radiation Biology, 58, 1025.
44. JOSEPH, P., JAISWAL, A.K, STOBBE, C.C. & CHAPMAN, J.D. (1994). The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles. International Journal of Radiation Oncology Biology Physics, 29, 351.
45. JOSEPHY, P.D., PALCIC, B & SKARSGARD, L.D (1981). In vitro metabolism of misonidazole. British Journal of Cancer, 43, 443.
46. KAGIYA, T. NISHIMOTO, S.I., SHIBAMOTO, Y, WANG, J., ZHOU L., HE, Y-L., SASAI, K., TAKAHASHI, M. & ABE, M. (1989). Importance of tumour affinity of nitroazoles in hypoxic radiosensitization. International Journal of Radiation Oncology Biology Physics, 16, 1033.
47. KOCH, CJ., EVANS, S.M. & LORD, E.M. (1995). Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts by fluorescent antibodies vs bound radioactivity. British Journal of Cancer, 72, 869.
48. KOH, W.J., BERGMAN, K S, RASEY, J.S., PETERSON. L M., EVANS, M.L., GRAHAM, M M , GRIERSON, J.R , LINDSLEY, K L., LEWELLEN, T.K., KROHN, K.A. & GRIFFIN, T.W (1995). Evaluation of oxygenation status during fractionated radiotherapy in human non small cell lung cancers using [F-18] fluoromisonidazole positron emission tomography. International Journal of Radiation Oncology Biology Physics, 33, 391.
49. 31P nuclear magnetic resonance with tumor growth in radioresistant and radiosensitive tumors. Radiation Research, 121, 312.
50. 19F magnetic resonance spectroscopy and immunohistochemistry. Radiation Research, 129, 71.
51. LEE, J., SIEMANN, D.W. KOCH, C.J. & LORD, E.M. (1996). Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. International Journal of Cancer, 67, 372.
52. 19F] magnetic resonance spectroscopy. Cancer Communications, 3, 133.
53. LORD, E.M., HARWELL, L. & KOCH, C.J (1993). Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Research, 53, 5721.
54. 2 inhibition of nitroreductase. Biochemical and Biophysics Research Commununications, 67, 1267.
55. 19F magnetic resonance spectroscopy in vivo. International Journal of Radiation Oncology Biology Physics, 16, 925.
56. MCCOY, C.L., MCINTYRE, D J O., ROBINSON, S.P., ABOAGYE, E.O & GRIFFITHS, J.R. (1996). Magnetic resonance spectroscopy and imaging methods for measuring tumor and tissue oxygenation. British Journal of Cancer, 74 (Suppl. XXVII), 226.
57. MCSHEEHY, PM J., ROBINSON, S.P., OJUGO, A.S.E., ABOAGYE, E.O., CANNELL, M.B, LEACH, M.O. & GRIFFITHS, JR. (1998). Carbogen breathing increases 5-fluorouracil uptake and cytotoxicity in hypoxic murine RIF-1 tumors: a magnetic resonance study in vivo. Cancer Research, in press.
58. MILLER, G.G., NGANLEE, J & CHAPMAN, J.D. (1982). Intracellular localization of radioactively labelled misonidazole in EMT-6 tumor cells in vitro. International Journal of Radiation Oncology Biology Physics, 8, 741.
59. _ MOULDER, J.E. & ROCKWELL, S. (1984). Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. International Journal of Radiation Oncology Biology Physics, 10, 695.
60. NEWMAN, H.F.V., BLEEHEN, N.M., WARD, N. & WORKMAN, P. (1988). Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole). International Journal of Radiation Oncology Biology Physics, 15, 1073.
61. 31P for non-invasive evaluation of tumor metabolic status. International Journal of Radiation Oncology Biology Physics, 12, 793.
62. OKUNIEFF, P., HOECKEL, M., DUNPHY, E.P, SCHLENGER, K., KNOOP, C & VAUPEL, P. (1993). Oxygen tension distributions are sufficient to explain the local response of human breast tumors treated with radiation alone. International Journal of Radiation Oncology Biology Physics, 26, 631.
63. OVERGAARD, J. (1992). Importance of tumor hypoxia in radiotherapy: a meta-analysis of controlled clinical trials. Radiotherapy and Oncology, 24, S64
64. OVERGAARD, J. (1994). Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncology Research, 6, 509.
65. PATTERSON, A V., SAUNDERS, M P., CHINJE, E.C , TALBOT D.C., HARRIS, A L. & STRATFORD, I.J. (1997). Over-expression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. British Journal of Cancer, 76, 1338.
66. RALEIGH, J.A., FRANKO, A J., TREIBER, E O., LUNT, J.A. & ALLEN, P.S (1986). Covalent binding of a fluorinated 2-nitroimidazole to EMT-6 tumors in BALB/c mice: Detection by 19-F nuclear magnetic resonance at 2.35 T. International Journal of Radiation Oncology Biology Physics, 12, 1243.
67. 19F magnetic resonance method for measuring oxygen deficiency in tumors. Magnetic Resonance in Medicine, 22, 451.
68. 2 distribution and bioreductive enzymes in human malignant brain tumors. International Journal of Radiation Oncology Biology and Physics, 29, 427.
69. 18F]fluoromisonidazole: a pretherapy study of 37 patients. International Journal of Radiation Oncology Biology Physics, 36, 417.
70. RAUTH, A.M (1984). Pharmacology and toxicology of sensitizers: mechanism studies. International Journal of Radiation Oncology Biology Physics, 10, 1293.
71. 2 cryospectrophotometry in prediction of tumor resistance caused by hypoxia. International Journal of Radiation Oncology Biology Physics, 16, 919.
72. RUSSO, C.A., WEBER, T.K., VOLPE, C.M., STOLER, D.L., PETRELLI, N.J, RODRIGUEZ-BIGAS, M., BURHANS, W.C & ANDERSON, GR. (1995). An anoxia inducible endonuclease and enhanced DNA breakage as contributors to genomic instability in cancer. Cancer Research, 55, 1122.
73. SASAI, K., SHIBAMOTO, Y., TAKAHASHI, M., ITO, T. NISHIMOTO, S. & ABE, M. (1990). Pharmacokinetics of 2-nitroimidazole hypoxic cell radiosensitizers in rodent peripheral nervous tissue. International Journal of Radiation Biology, 57, 971.
74. SHWEIKI, D., ITIN, A , SOFFER, D. & KESHET E. (1992). Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359, 843.
75. SHIBAMOTO, Y., TAKAHASHI, M. & ABE, M. (1996). A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy. Radiotherapy and Oncology, 40, 55.
76. SHIBAMOTO, Y., OHSHIO, G., HOSOTANI, R., NISHIMURA, Y, MAWABE, T., IMAMURA, M. & ABE, M. (1997). A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy. British Journal of Cancer, 76, 1474.
77. SOTAK. C.H., HEES, P.S., HUANG, H.N., HUANG, M.H , KRESPAN, C.G. & SUART, R. (1993). A new perfluorocarbon for use in fluorine-19 magnetic resonance spectroscopy. Magnetic Resonance in Medicine, 29, 188.
78. STRATFORD, I.J & WORKMAN, P. (1998). Bioreductive drugs into the next millenium. Anti-Cancer Drug Design, 13, 519.
79. 1. A scheme for analysis of in vivo metabolites. Journal of Magnetic Resonance, 55, 357.
80. TROTTER, M J., ACKER, B.D. & CHAPLIN, D.J. (1989). Histological evidence for non-perfused vasculature in a murine tumor following hydralazine administration. International Journal of Radiation Oncology Biology Physics, 17, 785.
81. URTASUN, R C., CHAPMAN. J.D., FELDSTEIN, M.L., BAND, R P., RABIN, H.R., WILSON, A F., MARYNOWSKI, B., STARREVELD, E. & SHNITKA, T (1978). Peripheral neuropathy related to misonidazole: incidence and pathology. British Journal Cancer, 37, S271.
82. 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. International Journal of Radiation Oncology Biology Physics, 12, 1263.
83. 2 at the cellular level. British Journal Cancer, 54, 453.
84. VAUPEL, P., KALLINOWSKI, F & OKUNIEFF, P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Research, 49, 6449.
85. 2 tension measurements. Cancer Research, 51, 3316.
86. WALTON, M & WORKMAN, P. (1987). Nitroimidazole bioreductive metabolism: quantitation and characterization of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochemical Pharmacology, 36, 887.
87. WARDMAN, P. (1977). The use of nitroaromatic compounds as hypoxia cell radiosensitizers. Current Topics in Radiation Research, 11, 347.
88. WARDMAN, P. & CLARKE, E.D (1976). Oxygen inhibition of nitroreductase: electron transfer from nitro radical-anions to oxygen. Biochemical and Biophysics Research Commununications, 69, 942.
89. WHITE, R.A.S. & WORKMAN, P (1980). Pharmacokinetics and tumor-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-9963) in dogs. British Journal of Cancer, 41, 268.
90. WHITE, R.A S., WORKMAN, P. & BROWN, J.M. (1980). The pharmacokinetics and tumor and neural tissue penetrating properties of SR 2508 and SR-2555 in the dog - hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiation Research, 84, 542.
91. WHITE, R.A.S., WORKMAN, P. & OWEN, L. (1982). The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole. International Journal of Radiation Oncology Biology Physics, 8, 473.
92. WORKMAN, P. (1979). Effects of pretreatment with phenobarbitone and phenytoin on the pharmacokinetics and toxicity of misonidazole in mice. British Journal of Cancer, 40, 335.
93. WORKMAN, P. (1980). Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemotherapy and Pharmacology, 5, 27.
94. WORKMAN, P. (1982). Lipophilicity and the pharmacokinetics of nitroimidazoles. In Advanced Topics on Radiosensitizers of Hypoxic Cells. Breccia, A., Rimondi, C. & Adams, G.E. (eds), p. 143. Plenum Press: Amsterdam.
95. WORKMAN, P (1983). Pharmacokinetics of radiosensitizing agents. In Pharmacokinetics of Anticancer Agents in Humans. Ames, M.M., Powis, G. & Kovach, J.S. (eds), p. 291. Elsevier Publishers: Amsterdam.
96. WORKMAN, P. (1992). Keynote address: bioreductive mechanisms. International Journal of Radiation Oncology Biology Physics, 22, 631.
97. WORKMAN, P. & BROWN, J.M. (1981). Structure-pharmacokinetic relationships for misonidazole analogs in mice. Cancer Chemotherapy and Pharmacology, 6, 39.
98. WORKMAN, P., MAXWELL, R H. & GRIFFITHS, J.R. (1992). Non-invasive MRS in new anticancer drug development. NMR in Biomedicine, 5, 270.
99. 2 receptor histamine antagonists. Journal of Medicinal Chemistry, 31, 656.